Search

Your search keyword '"Lei, Xiaoyong"' showing total 144 results
Start Over Author "Lei, Xiaoyong" Publication Year Range Last 3 years
144 results on '"Lei, Xiaoyong"'

12. From Human Oral Instructions to General Representations of Knowledge: A New Paradigm for Industrial Robots Skill Teaching

Author

Chen, Shiyu, Zhao, Yongjia, Lei, Xiaoyong, Qi, Tao, Liu, Kan, Filipe, Joaquim, Editorial Board Member, Ghosh, Ashish, Editorial Board Member, Prates, Raquel Oliveira, Editorial Board Member, Zhou, Lizhu, Editorial Board Member, Sun, Fuchun, editor, Hu, Dewen, editor, Wermter, Stefan, editor, Yang, Lei, editor, Liu, Huaping, editor, and Fang, Bin, editor

Published
2022
Full Text
View/download PDF

26. Microrna-96 In Human Cancers

Author

Yang, Xiaoyan, primary, Wu, Yiwen, additional, Xie, Zhizhong, additional, Deng, Sijun, additional, Xia, Yiniu, additional, and Lei, Xiaoyong, additional

Published
2023
Full Text
View/download PDF

28. The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia

Author

Zhang, Yuan, Wu, Xin, Sun, Xueyan, Yang, Jun, Liu, Chang, Tang, Guotao, Lei, Xiaoyong, Huang, Honglin, and Peng, Junmei

Abstract

Chronic myelogenous leukemia (CML) is a malignant myeloproliferative disease. According to the American Cancer Society's 2021 cancer data report, new cases of CML account for about 15% of all leukemias. CML is generally divided into three stages: chronic phase, accelerated phase, and blast phase. Nearly 90% of patients are diagnosed as a chronic phase. Allogeneic stem cell transplantation and chemotherapeutic drugs, such as interferon IFN-α were used as the earliest treatments for CML. However, they could generate obvious side effects, and scientists had to seek new treatments for CML. A new era of targeted therapy for CML began with the introduction of imatinib, the first-generation BCR-ABL kinase inhibitor. However, the ensuing drug resistance and mutant strains led by T315I limited the further use of imatinib. With the continuous advancement of research, tyrosine kinase inhibitors (TKI) and BCR-ABL protein degraders with novel structures and therapeutic mechanisms have been discovered. From biological macromolecules to classical target protein inhibitors, a growing number of compounds are being developed to treat chronic myelogenous leukemia. In this review, we focus on summarizing the current situation of a series of candidate small-molecule drugs in CML therapy, including TKIs and BCR-ABL protein degrader. The examples provided herein describe the pharmacology activity of small-molecule drugs. These drugs will provide new enlightenment for future treatment directions.

Published
2024
Full Text
View/download PDF

29. Variance state propagation for uplink channel estimation in LEO satellite systems.

Author

Lei, Xiaoyong, Zhang, Mingchen, Liu, Yilun, and Zhang, Yong

Subjects
*CHANNEL estimation, *ORTHOGONAL frequency division multiplexing, *DOPPLER effect, *ITERATIVE learning control
Abstract

This paper, considers the channel estimation problem of the uplink low Earth orbit (LEO) satellite orthogonal frequency division multiplexing (OFDM) system. By exploiting the channel structured sparsity in the delay‐Doppler‐angle domain, the channel estimation problem is formulated as a block‐sparse signal recovery problem. The variance state propagation (VSP) framework is extended to solve such a problem. Considering that the delay, Doppler shift, and angle of departure (AoD) of each propagation path may not exactly fall on the presumed discrete grid points, an expectation maximization (EM) based parameter learning scheme in VSP to iteratively update the grid parameters is introduced. Simulation results demonstrate that the proposed approach achieves a substantial performance gain over the existing methods. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Roles of ABCA1 in cancer

Author

Wu, Kun, Zou, Longwei, Lei, Xiaoyong, and Yang, Xiaoyan

Subjects
Review
Abstract

Studies have indicated that anticancer drugs targeting cholesterol metabolism have clinical significance. From the perspective of the mechanism of cholesterol excretion from cells, ATP-binding cassette (ABC)A1 has an essential role that cannot be ignored. ABCA1 is located on the cell membrane and able to mediate the efflux of lipids, such as intracellular cholesterol, thereby initiating reverse cholesterol transport to reduce the intracellular cholesterol level. Therefore, inducing the expression of ABCA1 may become a new breakthrough point in cancer therapy.

Published
2022

48. Discovery of a Potential Multi-Target Anti-Tumor Agent via Structural Modification on Flavonoid.

Author

Deng, Xiangping, Zou, Yang, Liu, Renbo, Peng, Yijiao, Ouyang, Chenglin, Peng, Junmei, Lei, Xiaoyong, Xie, Zhizhong, Li, Chong, and Tang, Guotao

Subjects
ANTINEOPLASTIC agents, ANNEXINS, FLAVONOIDS, DRUG development, CANCER cells, TUBULINS, BENZIMIDAZOLES
Abstract

A series of flavonoid derivatives bearing trimethoxyphenyl and benzimidazole were designed, synthesized and evaluated as potential anti-tumor agents. Compound 5g showed remarkable inhibitory activity against SGC-7901, HGC-27 and MCF-7 (IC50 values of 20.5 ± 5.93, 3.3 ± 2.53 and 16.6 ± 0.75 μM, respectively), and had great selectivity to cancer cells. The results of Hoechst 33258 staining and Annexin V-FITC/PI dual staining confirmed that compound 5 g induced apoptosis of the HGC-27 cells in a concentration-dependent manner. After treatment with compound 5 g, the expression of HIF-1α, VEGF and PKM2 were down-regulated, accompanied by weakened the levels of lactate. Further research revealed that compound 5 g could obviously inhibit tubulin assembly. In summary, compound 5 g possessed a promising potential for further development into anti-tumor drug candidates. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results